Merck & Co has announced a deal with King’s College London (KCL) and Wellcome to investigate a new class of painkillers that could provide an alternative to opioids and their dangerous side-effects.

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck licenses the protein, called berahyaluronidase alfa, from Alteogen. Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents.

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the latest in a series of cross-border deals between Western ...

Hengrui Pharma signed the agreement with Merck (NYSE: MRK) — known as MSD outside of the United States and Canada — for HRS-5346, its investigational oral small molecule Lipoprotein(a), or Lp ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8710 ...

Merck & Co. (MRK) releases positive phase three data for its injectable-form cancer drug Keytruda. Yahoo Finance Senior Health Reporter Anjalee Khemlani joins Market Domination to break down the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...